Healthcare | June 30, 2025
Fredun Pharmaceuticals acquires One Pet Stop to foray into pet care market
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
The pet dog population alone is expected to increase from 21.4 million in 2019 to 51.5 million by 2028
The company's decision to withdraw the MAA was due to the timing of the availability of Chemistry Manufacturing and Controls
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
Rising demands and advancements in eye care drive growth
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Dupixent (dupilumab) approved as the first-ever biologic medicine in Japan for patients with Chronic Obstructive Pulmonary Disease (COPD)
Subscribe To Our Newsletter & Stay Updated
